VertiGIS Enters Next Phase of Growth, Appoints Andy Berry as CEO
VertiGIS, a global market leader and provider of innovative spatial asset management solutions for utilities, telecommunications, government, and infrastructure organizations is entering its next phase of growth and expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005035/en/
London-based Andy Berry joins VertiGIS as CEO. (Photo: Business Wire)
VertiGIS is backed by global, technology-focused investment firm Battery Ventures, who saw an opportunity to bring together a distributed ecosystem of leading geographic information systems (GIS) and spatial technology companies under the brand in 2017. VertiGIS has since acquired 10 businesses in North America and Europe and shows no signs of slowing down; in fact, the company intends to grow both organically and through acquisition over the coming years to expand VertiGIS’s offerings into their target industries around the world.
Leading the charge for this new phase of rapid growth is London-based Andy Berry, who was recently appointed as VertiGIS’s CEO. Berry has an extensive background in growing global technology companies with executive roles at ZephyrTel, Pitney Bowes, and LogFire. In his most recent role as Executive Vice President (International, Compass Business Unit) at Infor he was responsible for USD $300 million of revenue across seven independent business units with over 100 products that served 20,000 customers in EMEA and Asia.
“It’s impressive to see how VertiGIS has come together and evolved over the past five years,” said Berry. “This next stage of our growth is all about innovation. While our customers can certainly rely upon us to continue supporting them with our trusted, in-market solutions, they can also expect to see us apply our decades of industry experience and research into cutting-edge technology as we continue to invest in configurable, cloud-ready software that solves their real-world challenges.”
Morad Elhafed, a Battery general partner and VertiGIS board member, noted: “We are thrilled to welcome Andy to the team to further VertiGIS’s mission, which has never been more important given recent geopolitical events impacting governments across Europe, a key VertiGIS customer segment. More broadly, we’re excited to support the company’s organic and inorganic growth strategies across all segments and geographies going forward.”
VertiGIS currently employs over 500 employees in nine countries and serves over 5,000 customers – ranging in size from small businesses and municipalities to global enterprises and major cities – around the world. Their proven, configurable solutions address challenges commonly faced by utilities, telecommunications, government, and infrastructure organizations, with use cases such as:
- Network management (planning, documentation, simulation, analytics);
- Citizen engagement;
- Land management and urban planning;
- Waste management;
- Facilities and asset management (critical infrastructure, large building operations, commercial spaces, manufacturing plants); and
- Transportation (roads, rail, airports, seaports).
VertiGIS solutions are powered by the flexible, purposeful capabilities (e.g., web and mobile viewers, reporting and printing designers, fine-grained security tools, intelligent workflows to digitize processes) found in their VertiGIS Studio™ suite, which can also be licensed separately to help customers extend, enhance, or create their own spatial applications quicker with configuration instead of writing costly custom code.
VertiGIS is a leading spatial asset management and geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, government, telecommunications, and infrastructure professionals connect their business processes to location technology. The VertiGIS product portfolio is used by over 5,000 customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Further information at www.vertigis.com.
About Battery Ventures:
Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Andy Berry, Chief Executive Officer – VertiGIS
Phone: +44 (0)7718 118689
Rebecca Buckman, Marketing Partner – Battery Ventures
Phone: +1 650 292 2077
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carbios Hosts World’s First PET Biorecycling Summit with Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker9.12.2022 08:45:00 EET | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005776/en/ Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker at the First World PET Biorecycling Summit organised by Carbios Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, hosted the world’s first PET Biorecycling Summit from 7 to 8 December 2022 in Paris. The event attracted over 100 international participants from the scientific, academic, and industrial worlds to exchange on the advances in the field of biological recycling, and how to bring these innovations for a circular economy to market. The two-day conference gathered world-renowned scientists from various academic institutions to share their latest research on PET enzymatic depolymerization. Bertrand Piccard, Initiator and Chairman
Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble™9.12.2022 06:30:00 EET | Press release
Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble ™ is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumble will release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005292/en/ Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble , fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer a
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release
Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the
TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release
TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom